December 1, 2014Cardiology in the Young

The current version of the 0.1 mm polytetrafluoroethylene valve conduit has excellent short-to-intermediate-term function without early calcification or thrombosis, though earlier designs experienced leaflet dehiscence.

View Full Paper

Ask AI

Bookmark

Why the study?

Does a bicuspid polytetrafluoroethylene valve conduit provide durable function without calcification or thrombosis in patients with congenital cardiac disease requiring pulmonary valve replacement?

Population

>200 patients with congenital cardiac disease and chronic pulmonary insufficiency requiring pulmonary valve…

Design

Case_series

Follow-up

up to 14 years

Authors

JQJames A. Quintessenza

Discussion

Member takes

Overview

Case report data should not alter valve selection; leaves open need for prospective durability trials in congenital pulmonary replacement.

Structured PICO

Does a bicuspid polytetrafluoroethylene valve conduit provide durable function without calcification or thrombosis in patients with congenital cardiac disease requiring pulmonary valve replacement?

Population

>200 patients with congenital cardiac disease and chronic pulmonary insufficiency requiring pulmonary valve replacement

Intervention

Bicuspid (bileaflet) polytetrafluoroethylene (PTFE) valve implantation (initially hand-sewn 0.6 mm and 0.1 mm, currently placed within a PTFE tube)

Outcome

Short-to-intermediate-term valve functionsurrogate

A bicuspid polytetrafluoroethylene pulmonary valve conduit offers a promising alternative to bioprostheses for pulmonary valve replacement in congenital heart disease, avoiding early calcification and the need for anticoagulation.

Limitations

Further follow-up is necessary to determine late durability and life-long valve-related procedural risk

Cite This Study

James A. Quintessenza (2014) studied this question.

synapsesocial.com/papers/6a7e30dad2dab736758561b0 https://doi.org/10.1017/s1047951114002200

View Full Paper

Ask AI

Bookmark

December 1, 2014Cardiology in the Young

The current version of the 0.1 mm polytetrafluoroethylene valve conduit has excellent short-to-intermediate-term function without early calcification or thrombosis, though earlier designs experienced leaflet dehiscence.

View Full Paper

Ask AI

Bookmark

Why the study?

Does a bicuspid polytetrafluoroethylene valve conduit provide durable function without calcification or thrombosis in patients with congenital cardiac disease requiring pulmonary valve replacement?

Population

>200 patients with congenital cardiac disease and chronic pulmonary insufficiency requiring pulmonary valve…

Design

Case_series

Follow-up

up to 14 years

Authors

JQJames A. Quintessenza

Discussion

Member takes

Overview

Case report data should not alter valve selection; leaves open need for prospective durability trials in congenital pulmonary replacement.

Structured PICO

Does a bicuspid polytetrafluoroethylene valve conduit provide durable function without calcification or thrombosis in patients with congenital cardiac disease requiring pulmonary valve replacement?

Population

>200 patients with congenital cardiac disease and chronic pulmonary insufficiency requiring pulmonary valve replacement

Intervention

Bicuspid (bileaflet) polytetrafluoroethylene (PTFE) valve implantation (initially hand-sewn 0.6 mm and 0.1 mm, currently placed within a PTFE tube)

Outcome

Short-to-intermediate-term valve functionsurrogate

Limitations

Further follow-up is necessary to determine late durability and life-long valve-related procedural risk

Cite This Study

James A. Quintessenza (2014) studied this question.

synapsesocial.com/papers/6a7e30dad2dab736758561b0 https://doi.org/10.1017/s1047951114002200

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark